Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial

#3520

Introduction: TGR has been investigated as a potential biomarker for antitumor drug activity in NETs.

Aim(s): Assess impact of reducing LAN dosing interval on TGR in patients with progressive midgut or pancreatic (pan)NETs.

Materials and methods: CLARINET FORTE (NCT02651987) included patients receiving LAN 120mg/28 days (n=51 midgut; 48 panNET), with progressive disease (PD) for ≥24 weeks (wks) prior to study entry. On study entry, LAN dosing interval was reduced to 14 days. CT and MRI scans were reviewed centrally to assess progression. TGR was expressed as % increase in target tumor volume per month (M), accounting for change in tumor size (defined as sum of diameters of target lesions). Baseline (BL) TGR was categorized by interval between historical and BL scans (<12M and ≥12M).

Conference:

Presenting Author:

Authors: Dromain C, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Tumor Growth Rate, Lanreotide Autogel, midgut, pancreatic,